Management and Prognosis of Interstitial Lung Disease With Lung Cancer (ILD-LC): A Real-World Cohort From Three Medical Centers in China

Overview

Journal Front Mol Biosci

Specialty Biology

Date 2021 Apr 19

PMID 33869290

Citations 5

Authors

Xie Xiaohong

Wang LiQiang

Li Na

Lin Xinqing

Qin Yinyin

Liu Ming

Ouyang Ming

Han Qian

Luo Qun

Li Shiyue

Li Chunyan

Wang Xiaoqian

Yang Shuanying

Huang Wei

Liu Mei

Wang Ping

Zhou Chengzhi

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Interstitial lung disease with lung cancer (ILD-LC) is rare and its management has not been fully described. This study aimed to investigate the management and prognosis of ILD-LC patients in China.

Methods: The present analysis is a retrospective real-world cohort study. Clinical data of ILD-LC patients were obtained from 3 hospitals in China. The overall survival (OS) of patients was analyzed. Univariate and multivariate regression analyses were performed.

Results: One hundred eighty-four ILD-LC patients included were biased toward male (85.3%), smokers (75.5%), idiopathic pulmonary fibrosis (IPF) (58.2%) patients with comorbidities (67.9%) and ECOG-PS score of 1 (65.2%). Most patients were advanced peripheral non-small cell lung cancer. The initial anti-cancer regimen for ILD-LC is mainly chemotherapy, and patients with early-stage LC prefer surgery. In the anti-cancer cohort, the number of ILD-LC patients who underwent the 2nd and 3rd or more anti-cancer regimens were 78 (55.7%) and 32 (22.8%), respectively. In the non-anticancer cohort, the median OS was 3.5 months. In the early-stage cohort, the median OS was 14.2 months in the systematic therapy group; however, the median OS was not reached in the surgery group. In the advanced-stage cohort with systematic therapy, the median OS was 7.2 months. Interstitial pneumonia (IIP) and anti-angiogenesis were associated with OS in the univariate analysis, whereas anti-angiogenesis was an independent protective factor for advanced LC with ILD.

Conclusion: Patients with ILD-LC have very poor prognosis. Appropriate anti-tumor treatment can prolong the survival time of patients who can tolerate it. Targeted therapy and immunotherapy are alternative treatments for LC patients with mild ILD. For ILD patients with advanced LC, antiangiogenic regimens significantly improve the prognosis of the disease.

Citing Articles

Long term survival of advanced hepatoid adenocarcinoma of lung secondary to idiopathic pulmonary fibrosis: a case report.

Wang X, Wei N, Yang H, Wang X, Zhang X, Zhang Q Front Oncol. 2025; 15:1487334.

PMID: 39968074 PMC: 11832387. DOI: 10.3389/fonc.2025.1487334.

Impact of interstitial lung disease gender-age-physiology index in surgically treated lung cancer.

Sakamoto S, Kawakita N, Takeuchi T, Sumitomo H, Miyamoto N, Toba H Int J Clin Oncol. 2024; 29(10):1475-1482.

PMID: 39180709 DOI: 10.1007/s10147-024-02600-5.

A nomogram for the prediction of the survival of patients with advanced non-small cell lung cancer and interstitial lung disease.

Xiu W, Zheng J, Zhou Y, Du H, Li J, Li W Cancer Med. 2023; 12(10):11375-11384.

PMID: 36999934 PMC: 10242331. DOI: 10.1002/cam4.5852.

Immunotherapy for combined pulmonary fibrosis and emphysema with advanced lung cancer: two case reports and a concise review.

Tan X, Tang X, Jiang Y Transl Cancer Res. 2022; 11(11):4194-4199.

PMID: 36523303 PMC: 9745352. DOI: 10.21037/tcr-22-1526.

Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database.

Barbieri M, Sorbara E, Cicala G, Santoro V, Cutroneo P, Franchina T Front Oncol. 2022; 12:1005626.

PMID: 36505840 PMC: 9727240. DOI: 10.3389/fonc.2022.1005626.

References

Kenmotsu H, Naito T, Mori K, Ko R, Ono A, Wakuda K . Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. Cancer Chemother Pharmacol. 2015; 75(3):521-6. DOI: 10.1007/s00280-014-2670-y. View

Sekine A, Satoh H, Baba T, Ikeda S, Okuda R, Shinohara T . Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study. Cancer Chemother Pharmacol. 2016; 77(6):1245-52. DOI: 10.1007/s00280-016-3040-8. View

Tone M, Izumo T, Awano N, Kuse N, Inomata M, Jo T . High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer. Thorac Cancer. 2019; 10(10):2006-2012. PMC: 6775002. DOI: 10.1111/1759-7714.13187. View

Raghu G, Nyberg F, MORGAN G . The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer. 2004; 91 Suppl 2:S3-10. PMC: 2750810. DOI: 10.1038/sj.bjc.6602061. View

Kobayashi H, Naito T, Omae K, Omori S, Nakashima K, Wakuda K . Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy. J Cancer. 2018; 9(11):2054-2060. PMC: 5995939. DOI: 10.7150/jca.24936. View

Minegishi Y, Sudoh J, Kuribayasi H, Mizutani H, Seike M, Azuma A . The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer. 2010; 71(1):70-4. DOI: 10.1016/j.lungcan.2010.04.014. View

Shi L, Tang J, Tong L, Liu Z . Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. Lung Cancer. 2013; 83(2):231-9. DOI: 10.1016/j.lungcan.2013.11.016. View

Richeldi L, du Bois R, Raghu G, Azuma A, Brown K, Costabel U . Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2071-82. DOI: 10.1056/NEJMoa1402584. View

Saijo A, Hanibuchi M, Goto H, Toyoda Y, Tezuka T, Nishioka Y . An analysis of the clinical features of lung cancer in patients with connective tissue diseases. Respir Investig. 2017; 55(2):153-160. DOI: 10.1016/j.resinv.2016.11.003. View

10.

Homma S, Bando M, Azuma A, Sakamoto S, Sugino K, Ishii Y . Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respir Investig. 2018; 56(4):268-291. DOI: 10.1016/j.resinv.2018.03.003. View

11.

In Jung H, Park J, Lee M, Park B, Kim H, Park S . Prevalence of lung cancer in patients with interstitial lung disease is higher than in those with chronic obstructive pulmonary disease. Medicine (Baltimore). 2018; 97(11):e0071. PMC: 5882384. DOI: 10.1097/MD.0000000000010071. View

12.

Kato T, Masuda N, Nakanishi Y, Takahashi M, Hida T, Sakai H . Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer. Lung Cancer. 2017; 104:111-118. DOI: 10.1016/j.lungcan.2016.12.016. View

13.

Asahina H, Oizumi S, Takamura K, Harada T, Harada M, Yokouchi H . A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302). Lung Cancer. 2019; 138:65-71. DOI: 10.1016/j.lungcan.2019.09.020. View

14.

Enomoto Y, Inui N, Yoshimura K, Nishimoto K, Mori K, Kono M . Lung cancer development in patients with connective tissue disease-related interstitial lung disease: A retrospective observational study. Medicine (Baltimore). 2016; 95(50):e5716. PMC: 5268067. DOI: 10.1097/MD.0000000000005716. View

15.

Simler N, Brenchley P, Horrocks A, Greaves S, Hasleton P, Egan J . Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax. 2004; 59(7):581-5. PMC: 1747058. DOI: 10.1136/thx.2003.009860. View

16.

McKeown S, Richter A, OKane C, McAuley D, Thickett D . MMP expression and abnormal lung permeability are important determinants of outcome in IPF. Eur Respir J. 2008; 33(1):77-84. DOI: 10.1183/09031936.00060708. View

17.

Sato T, Teramukai S, Kondo H, Watanabe A, Ebina M, Kishi K . Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2013; 147(5):1604-1611.e3. DOI: 10.1016/j.jtcvs.2013.09.050. View

18.

Yamaguchi S, Ohguri T, Ide S, Aoki T, Imada H, Yahara K . Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer. 2013; 82(2):260-5. DOI: 10.1016/j.lungcan.2013.08.024. View

19.

Hanibuchi M, Kakiuchi S, Atagi S, Ogushi F, Shimizu E, Haku T . A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease. Lung Cancer. 2018; 125:93-99. DOI: 10.1016/j.lungcan.2018.09.007. View

20.

Kawahara T, Sakashita H, Suzuki T, Tateishi T, Miyazaki Y . Real world data of combined lung cancer and interstitial lung disease. J Thorac Dis. 2019; 11(10):4144-4151. PMC: 6837971. DOI: 10.21037/jtd.2019.10.01. View